Skip to main content

Table 2 Biochemical data before and after ezetimibe treatment

From: Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency

  Patient 1 Patient 2 Patient 3
  Baseline E10 E10 + A10 Baseline E10 E10 + A10 Baseline E10
ALT (IU/L) 137.2 ± 37.1 79.1 ± 12.8** 88.5 ± 28.5** 186.7 ± 41.8 88.2 ± 26.5** 84.9 ± 21.1** 115.0 76.3 ± 7.2
TC (mmol/L) 7.36 ± 0.75 5.54 ± 0.50** 4.40 ± 0.82**† 7.98 ± 0.84 6.59 ± 1.22** 4.37 ± 0.42**† 7.70 5.92 ± 0.44
HDL-C (mmol/L) 0.96 ± 0.07 1.01 ± 0.06 0.95 ± 0.06 0.95 ± 0.07 0.96 ± 0.05 0.93 ± 0.07 0.82 0.80 ± 0.04
LDL-C (mmol/L) 5.60 ± 0.77 3.94 ± 0.55** 2.92 ± 0.78**† 6.17 ± 0.80 5.02 ± 1.19* 2.87 ± 0.40**† 6.34 4.71 ± 0.42
TG (mmol/L) 1.94 ± 0.62 1.25 ± 0.24* 1.18 ± 0.43* 2.24 ± 0.47 1.43 ± 0.63* 1.29 ± 0.45** 1.25 0.82 ± 0.19
  1. Baseline values were calculated as mean values of the 3 years preceding the start of treatment for patient 1 and patient 2 and as value at the diagnosis, before the start of treatment for patient 3; E10 = ezetimibe 10 mg/day; A10 = atorvastatin 10 mg/day. Wilcoxon test: *P < 0.05 vs baseline; **P < 0.02 vs baseline; †P < 0.02 vs E10. ALT reference 10–45 IU/L; Total Cholesterol (TC) reference value below 5.17 mmol/L, Triglycerides (TG) reference value 0.3–1.7 mmol/L, HDL cholesterol (HDL-C) reference value above 1.16 mmmol/L, LDL cholesterol (LDL-C) reference value below 3.36 mmol/L